The company said that analyses and modeling of mutations in the variant suggest that they may weaken the effect of the treatment, but that studies using Omicron’s full sequences are incomplete.The company said that analyses and modeling of mutations in the variant suggest that they may weaken the effect of the treatment, but that studies using Omicron’s full sequences are incomplete.Antibodies, Coronavirus Omicron Variant, Regeneron Pharmaceuticals Inc, Coronavirus (2019-nCoV), Vaccination and ImmunizationRead More
